Author Login IJIRT Partner Network (IPN) Login

Review Paper of Dostarlimab

  • Unique Paper ID: 161881
  • Volume: 10
  • Issue: 6
  • PageNo: 487-492
  • Abstract:
  • Dostarlimab is a monoclonal antibody that blocks the programmed cell death protein 1 (PD-1) receptor from interacting with its ligands, PD-L1 and PD-L2. This interaction between PD-1 and its ligands can suppress the immune system's ability to attack cancer cells. By blocking this interaction, dostarlimab can help to unleash the immune system to fight cancer.Dostarlimab is also generally well-tolerated with a relatively mild side effect profile. The most common side effects are fatigue, nausea, diarrhea, and rash. These side effects are typically mild and manageable, and they often go away on their own or with supportive care.Dostarlimab is a relatively new drug, and it is still too early to say what its long-term safety and efficacy are. However, the results from clinical trials so far have been very promising. We will discuss the mechanism of action, trial phase performance and side effects of Dostarlimab drug.
Download article email to a friend

Cite This Article

  • ISSN: 2349-6002
  • Volume: 10
  • Issue: 6
  • PageNo: 487-492

Review Paper of Dostarlimab

Related Articles

Impact Factor
8.01 (Year 2024)
UGC Approved
Journal no 47859

Join Our IPN

IJIRT Partner Network

Submit your research paper and those of your network (friends, colleagues, or peers) through your IPN account, and receive 800 INR for each paper that gets published.

Join Now

Latest Publication

Archive

View More

Recent Conferences

NCSEM 2024

National Conference on Sustainable Engineering and Management - 2024 Last Date: 15th March 2024

Submit inquiry